

**DRIEHAUS CAPITAL MANAGEMENT LLC**

Driehaus Event Driven Fund Portfolio  
as of 12/31/2019

**Security Name**

14NEW ONCOLOGY INC	PRIVATE EQUITY
ABBVIE INC	
ADAPTHEALTH CORP	HOLDINGS WARRANTS
ALLERGAN PLC	
ALPHATEC HOLDINGS IN	COM
APTOSE BIOSCIENCES I	COM NEW
ARGENX SE	SPONSORED ADR
ARROW BIDCO LLC	9.5000% 03/15/24
ASCENDIS PHARMA A S	SPONSORED ADR
ASURION	BANKDEBT 8/04/2025
AVON PRODS INC	6.9500% 03/15/43
BELLUS HEALTH INC NE	COM NEW
BLUEPRINT MEDICINES	COM
CEC ENTERTAINMENT	8.000% 02/15/2022
CERENCE	TERM LOAN 10/01/2024
CLEAR CHANNEL	OUTDOOR HOLDINGS INC
CONSOLIDATED	COMMUNICATIONS
CONSOLIDATED COMMUNI	6.5000% 10/01/22
CYTOKINETICS INC	4.0000% 11/15/26
CYTOKINETICS INC	
DIAMOND EAGLE ACQUIS	UNIT EX 063026
EIG INVS CORP	10.8750% 02/01/24
EURO CURRENCY	
FGL HOLDINGS	
FOSSIL GROUP INC	TERM LOAN 09/26/2024
GENERAL MTRS CORP	DEB SR CV C ESCROW
GENERAL MTRS CORP	DEB SR CONV B ESCROW
GOGO INC	6.0000% 05/15/22
HARBORONE BANCORP IN	COM
HC2 HLDGS INC	11.5000% 12/01/21
HC2 HOLDINGS INC	
HEALTHCARE MERGER CO	UNIT EX 121721
HEARTLAND DENTAL LLC	8.5000% 05/01/26
HERBALIFE NUTRITION	LTD
HLF FING SARL LLC H	7.2500% 08/15/26
IDEAYA BIOSCIENCES I	COM
ILFC E-CAPITAL TR I	VAR RT 12/21/65
ISHARES NASDAQ	BIOTECHNOLOGY ETF
KEARNY FINL CORP	COM
MEDICINES COMPANY	
MERUS N V	COM
MYOKARDIA INC	COM
NEPBRO TL 2L	BANKDEBT 10/19/2026
OCEANFIRST FINL CORP	COM
ODONATE THERAPEUTICS	COM
ORCHARD THERAPEUTICS	PLC
SI BONE INC	COM

SPDR S&P REGIONAL	BANKING ETF
SPDR SERIES TRUST	S&P BIOTECH
SUTRO BIOPHARMA INC	COM
TREVI THERAPEUTICS I	COM
USB REALTY CORP	VAR RT PERPETUAL
VAPOTHERM INC	COM
VECTOR GROUP LTD	6.1250% 02/01/25
VECTOR GROUP LTD	COM
VIEWRAY INC	COM
X4 PHARMACEUTICALS	HOLDINGS WARRANTS
ZAYO GROUP HLDGS INC	COM

Source: Driehaus Capital Management LLC

The portfolio represents holdings for the Driehaus Event Driven Fund (the "Fund") as of the specified date. The Fund assumes no obligation to update or supplement the holdings to reflect subsequent changes. The holdings posted may not represent current or future portfolio composition or holdings and are subject to change without notice. Information on particular holdings may be withheld if it is in the Fund's best interest to do so. The holdings are unaudited and are provided for general information on the Fund. For more information please contact us at 877-779-0079. For information regarding the Fund's policy for valuation of investments and other significant accounting policies, please refer to the Fund's recent Semi-Annual or Annual financial statements.